As of 2025-09-15, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (51.04) USD. This relative valuation is based on P/E multiples. With the latest stock price at 46.99 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -208.6%.
The range of the Relative Valuation is (40.99) - (58.32) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 15.1x | 13.3x |
| Forward P/E multiples | 8.1x - 16.6x | 13.2x |
| Fair Price | (40.99) - (58.32) | (51.04) |
| Upside | -187.2% - -224.1% | -208.6% |
| Date | P/E |
| 2025-09-15 | -12.19 |
| 2025-09-12 | -12.20 |
| 2025-09-11 | -11.99 |
| 2025-09-10 | -11.29 |
| 2025-09-09 | -11.29 |
| 2025-09-08 | -11.23 |
| 2025-09-05 | -11.29 |
| 2025-09-04 | -10.95 |
| 2025-09-03 | -11.24 |
| 2025-09-02 | -10.56 |
| 2025-08-29 | -10.70 |
| 2025-08-28 | -10.84 |
| 2025-08-27 | -10.97 |
| 2025-08-26 | -11.39 |
| 2025-08-25 | -10.86 |
| 2025-08-22 | -11.45 |
| 2025-08-21 | -11.06 |
| 2025-08-20 | -10.99 |
| 2025-08-19 | -11.05 |
| 2025-08-18 | -11.32 |
| 2025-08-15 | -11.07 |
| 2025-08-14 | -10.79 |
| 2025-08-13 | -10.57 |
| 2025-08-12 | -10.35 |
| 2025-08-11 | -9.78 |
| 2025-08-08 | -10.54 |
| 2025-08-07 | -10.60 |
| 2025-08-06 | -10.73 |
| 2025-08-05 | -11.15 |
| 2025-08-04 | -11.33 |
| 2025-08-01 | -11.15 |
| 2025-07-31 | -11.36 |
| 2025-07-30 | -11.44 |
| 2025-07-29 | -11.34 |
| 2025-07-28 | -11.47 |
| 2025-07-25 | -11.89 |
| 2025-07-24 | -11.90 |
| 2025-07-23 | -12.05 |
| 2025-07-22 | -11.88 |
| 2025-07-21 | -11.72 |
| 2025-07-18 | -11.99 |
| 2025-07-17 | -12.03 |
| 2025-07-16 | -11.81 |
| 2025-07-15 | -11.66 |
| 2025-07-14 | -11.66 |
| 2025-07-11 | -11.55 |
| 2025-07-10 | -11.74 |
| 2025-07-09 | -11.73 |
| 2025-07-08 | -11.27 |
| 2025-07-07 | -11.37 |